Glucocorticoid exposure peaks early after rheumatoid arthritis diagnosis
Glucocorticoids remained a central part of early rheumatoid arthritis care in this Danish cohort, but the pattern was not one of sustained high-dose use. Among 574 newly diagnosed patients treated at Department of Rheumatology Aalborg University Hospital between 2014 and 2022, 428 patients, or 75%, received glucocorticoids during the first year after treatment initiation. More than half of the cohort, 313 patients, started treatment at the first visit, reflecting how often clinicians still rely on rapid anti-inflammatory control before longer-term disease-modifying therapy fully takes hold.
The average prescribed daily dose was 9.3 mg. A near-even split between formulations also stood out: 262 patients received tablets and 270 received intra-articular injection. Those numbers fit the practical reality of rheumatoid arthritis management, where systemic steroids and joint-directed treatment are often used to calm active synovitis quickly while clinicians try to avoid prolonged exposure. Inflammatory burden tends to be greatest near diagnosis, when pain, stiffness, and swollen joints are most severe, which helps explain why glucocorticoid use clustered at the beginning of care and then fell over time.
A single sentence captures the clinical arc: glucocorticoid exposure was front-loaded, not sustained.
Dose fell after the first visit as treatment settled
The study tracked physician-prescribed daily glucocorticoid dose during the first year after the initial rheumatology visit and found a clear downward trajectory. Dosages were highest early in the disease course and then declined substantially after the first consultation. This pattern suggests a deliberate tapering strategy rather than long-term dependence on steroids, which is consistent with modern rheumatoid arthritis practice that tries to use glucocorticoids as bridge therapy rather than maintenance treatment.
That taper matters biologically. Glucocorticoids suppress cytokine signaling, dampen leukocyte trafficking, and rapidly relieve synovial inflammation, but the same immunosuppressive effects can impair host defense. In rheumatoid arthritis, the tension is immediate: the medication that improves pain and swelling fastest is also the one that can raise concern about infection risk when exposure is repeated or prolonged. The cohort’s prescribing pattern shows clinicians appear to have balanced those competing pressures by reducing dose over time.
Nearly half of the patients received tablets, and nearly half received intra-articular injections, showing how treatment was distributed across systemic and localized approaches. The abstract does not provide granular detail on the sequence of those interventions, but the overall picture is consistent with stepwise care in which early inflammation is treated aggressively and then de-escalated as disease control improves.
Infection outcomes remained statistically uncertain at one year
Infections were common enough to be clinically relevant, but the one-year dose-response analysis did not establish a precise increase in risk for low-dose exposure. Overall, 117 patients, or 20%, experienced an infection within the first year. For the secondary endpoint, investigators used modified Poisson regression and compared non-exposed patients with those receiving low-dose glucocorticoids, defined as 0 to 10 mg/day from a 21-day average, and high-dose exposure above 10 mg/day.
After adjustment for asthma or chronic obstructive pulmonary disease, sex, and age, the relative risk for first infection with low-dose exposure versus non-exposure was 1.13, with a 95% confidence interval from 0.77 to 1.67. The interval crossed unity and was wide enough to accommodate both no clinically important effect and a meaningful increase in risk. In plain terms, the data did not settle the infection question; they left the estimate imprecise.
The uncertainty is important because infection risk is one of the main reasons rheumatologists try to shorten glucocorticoid exposure. Steroids can blunt the immune response even at relatively modest doses, but the actual risk in real-world rheumatoid arthritis patients depends on disease severity, comorbidity burden, background immunosuppression, and how long the drug is continued. Here, the available estimate was compatible with benefit and harm, which means the cohort cannot rule out either scenario.
Real-world prescribing suggests tapering, but risk estimates need sharper definition
This cohort gives a useful snapshot of everyday care in a Danish rheumatology service. Most patients received glucocorticoids at some point in the first year, and many began them immediately at diagnosis, which reinforces how embedded these drugs remain in early rheumatoid arthritis treatment. At the same time, the measured decline in dose after the initial visit suggests physicians were not allowing exposure to drift upward unchecked.
For bedside practice, the message is less about abandoning glucocorticoids and more about using them with discipline. Early relief can be clinically valuable, especially while disease-modifying therapy is taking effect, but prolonged exposure is where safety concerns become harder to ignore. The cohort’s infection analysis does not prove that low-dose treatment is harmless, and it does not prove that it is dangerous. It shows that, within this dataset, the signal was too imprecise to anchor a firm risk estimate.
The result also fits the limitations of observational work in a common, heterogeneous disease. Patients who receive glucocorticoids may differ from those who do not in ways that are not fully captured by age, sex, and airway disease status. Disease activity, serologic burden, prior treatment response, and other immunosuppressive medications can all influence infection risk, yet those factors are not fully resolved in the abstract. The confidence interval reflects that complexity.
A second sentence is worth isolating: the infection estimate was not definitive enough to settle practice.
What this cohort adds to early rheumatoid arthritis care
The study strengthens a straightforward clinical point: glucocorticoids are still heavily used at rheumatoid arthritis diagnosis, but exposure appears to shrink after the first visit rather than persist through the year. That pattern suggests a real-world effort to keep steroids in the bridge-therapy role they were meant to fill. In parallel, the infection analysis reminds clinicians that safety remains an open statistical question in routine care, especially when dose averages are low and patient-level confounding is difficult to eliminate.
The most defensible reading is practical rather than triumphant. Early glucocorticoid use remains common, dose falls after diagnosis, and the one-year infection estimate at low dose remains inconclusive. Future work will need tighter exposure measurement, better accounting for disease activity and concomitant therapy, and larger numbers of infection events if the field wants a more exact answer on where the balance between symptom relief and infectious harm truly lies.